Serina Therapeutics (SER) Operating Expenses (2018 - 2026)

Serina Therapeutics has disclosed Operating Expenses across 9 years of filings, most recently posting $6.8 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 19.12% year-over-year to $6.8 million; the TTM figure through Jun 2026 stood at $25.1 million (up 11.89% YoY), while the FY2025 annual figure was $24.2 million, up 41.21% from the prior year.
• Operating Expenses came in at $6.8 million for Q2 2026 at Serina Therapeutics, up from $6.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $6.8 million in Q2 2026 to a low of $952000.0 in Q2 2023.
• Average Operating Expenses over 5 years is $3.6 million, with a median of $2.8 million recorded in 2023.
• Year-over-year, Operating Expenses slumped 51.75% in 2023 and soared 311.45% in 2024.
• Over 5 years, Operating Expenses stood at $1.8 million in 2022, then jumped by 59.08% to $2.8 million in 2023, then soared by 94.48% to $5.5 million in 2024, then gained by 12.14% to $6.2 million in 2025, then gained by 9.3% to $6.8 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $6.8 million in Q2 2026, $6.2 million in Q4 2025, and $6.4 million in Q3 2025.